Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Highly diversified shrew hepatitis B viruses corroborate ancient origins and divergent infection patterns of mammalian hepadnaviruses.

Rasche A, Lehmann F, König A, Goldmann N, Corman VM, Moreira-Soto A, Geipel A, van Riel D, Vakulenko YA, Sander AL, Niekamp H, Kepper R, Schlegel M, Akoua-Koffi C, Souza BFCD, Sahr F, Olayemi A, Schulze V, Petraityte-Burneikiene R, Kazaks A, Lowjaga KAAT, Geyer J, Kuiken T, Drosten C, Lukashev AN, Fichet-Calvet E, Ulrich RG, Glebe D, Drexler JF.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):17007-17012. doi: 10.1073/pnas.1908072116. Epub 2019 Aug 1.

PMID:
31371507
2.

Why all blood donations should be tested for hepatitis E virus (HEV).

Denner J, Pischke S, Steinmann E, Blümel J, Glebe D.

BMC Infect Dis. 2019 Jun 20;19(1):541. doi: 10.1186/s12879-019-4190-1.

3.

Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling.

Gerresheim GK, Bathke J, Michel AM, Andreev DE, Shalamova LA, Rossbach O, Hu P, Glebe D, Fricke M, Marz M, Goesmann A, Kiniry SJ, Baranov PV, Shatsky IN, Niepmann M.

Int J Mol Sci. 2019 Mar 15;20(6). pii: E1321. doi: 10.3390/ijms20061321.

4.

Host Biology and Anthropogenic Factors Affect Hepadnavirus Infection in a Neotropical Bat.

Hiller T, Rasche A, Brändel SD, König A, Jeworowski L, Teague O'Mara M, Cottontail V, Page RA, Glebe D, Drexler JF, Tschapka M.

Ecohealth. 2019 Mar;16(1):82-94. doi: 10.1007/s10393-018-1387-5. Epub 2018 Dec 18.

PMID:
30564998
5.

Author Correction: Ancient hepatitis B viruses from the Bronze Age to the Medieval period.

Muhlemann B, Jones TC, de Barros Damgaard P, Allentoft ME, Shevnina I, Logvin A, Usmanova E, Panyushkina IP, Boldgiv B, Bazartseren T, Tashbaeva K, Merz V, Lau N, Smrčka V, Voyakin D, Kitov E, Epimakhov A, Pokutta D, Vicze M, Price TD, Moiseyev V, Hansen AJ, Orlando L, Rasmussen S, Sikora M, Vinner L, Osterhaus ADME, Smith DJ, Glebe D, Fouchier RAM, Drosten C, Sjogren KG, Kristiansen K, Willerslev E.

Nature. 2018 Oct;562(7726):E4. doi: 10.1038/s41586-018-0406-6.

PMID:
30108364
6.

Hepatitis B virus subgenotype F3 reactivation with vaccine escape mutations: A case report and review of the literature.

Schlabe S, van Bremen K, Aldabbagh S, Glebe D, Bremer CM, Marsen T, Mellin W, Cristanziano VD, Eis-Hübinger AM, Spengler U.

World J Hepatol. 2018 Jul 27;10(7):509-516. doi: 10.4254/wjh.v10.i7.509.

7.

Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model.

Nielsen KO, Jacobsen KS, Mirza AH, Winther TN, Størling J, Glebe D, Pociot F, Hogh B.

Exp Cell Res. 2018 Oct 1;371(1):92-103. doi: 10.1016/j.yexcr.2018.07.044. Epub 2018 Jul 27.

8.

Hepatitis B virus suppresses the secretion of insulin-like growth factor binding protein 1 to facilitate anti-apoptotic IGF-1 effects in HepG2 cells.

Nielsen KO, Mirza AH, Kaur S, Jacobsen KS, Winther TN, Glebe D, Pociot F, Hogh B, Størling J.

Exp Cell Res. 2018 Sep 15;370(2):399-408. doi: 10.1016/j.yexcr.2018.07.002. Epub 2018 Jul 4.

9.

Characterisation of the hepatitis B virus cross-species transmission pattern via Na+/taurocholate co-transporting polypeptides from 11 New World and Old World primate species.

Müller SF, König A, Döring B, Glebe D, Geyer J.

PLoS One. 2018 Jun 18;13(6):e0199200. doi: 10.1371/journal.pone.0199200. eCollection 2018.

10.

Tenofovir to Prevent Perinatal Transmission of Hepatitis B.

Gerlich W, Glebe D.

N Engl J Med. 2018 Jun 14;378(24):2349. doi: 10.1056/NEJMc1805396. No abstract available.

PMID:
29900726
11.

Ancient hepatitis B viruses from the Bronze Age to the Medieval period.

Mühlemann B, Jones TC, Damgaard PB, Allentoft ME, Shevnina I, Logvin A, Usmanova E, Panyushkina IP, Boldgiv B, Bazartseren T, Tashbaeva K, Merz V, Lau N, Smrčka V, Voyakin D, Kitov E, Epimakhov A, Pokutta D, Vicze M, Price TD, Moiseyev V, Hansen AJ, Orlando L, Rasmussen S, Sikora M, Vinner L, Osterhaus ADME, Smith DJ, Glebe D, Fouchier RAM, Drosten C, Sjögren KG, Kristiansen K, Willerslev E.

Nature. 2018 May;557(7705):418-423. doi: 10.1038/s41586-018-0097-z. Epub 2018 May 9. Erratum in: Nature. 2018 Oct;562(7726):E4.

PMID:
29743673
12.

A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.

de Carvalho Dominguez Souza BF, König A, Rasche A, de Oliveira Carneiro I, Stephan N, Corman VM, Roppert PL, Goldmann N, Kepper R, Müller SF, Völker C, de Souza AJS, Gomes-Gouvêa MS, Moreira-Soto A, Stöcker A, Nassal M, Franke CR, Rebello Pinho JR, Soares MDCP, Geyer J, Lemey P, Drosten C, Netto EM, Glebe D, Drexler JF.

J Hepatol. 2018 Jun;68(6):1114-1122. doi: 10.1016/j.jhep.2018.01.029. Epub 2018 Feb 8.

13.

[Overexpression of DNA-methyltransferases in persistency of cccDNA pool in chronic hepatitis B].

Kostyushev DS, Zueva AP, Brezgin SA, Lipatnikov AD, Simirskii VN, Glebe D, Volchkova EV, Shipulin GA, Chulanov VP.

Ter Arkh. 2017;89(11):21-26. doi: 10.17116/terarkh2017891121-26. Russian.

PMID:
29260742
14.

Activity of nucleic acid polymers in rodent models of HBV infection.

Schöneweis K, Motter N, Roppert PL, Lu M, Wang B, Roehl I, Glebe D, Yang D, Morrey JD, Roggendorf M, Vaillant A.

Antiviral Res. 2018 Jan;149:26-33. doi: 10.1016/j.antiviral.2017.10.022. Epub 2017 Nov 8.

15.

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.

Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F.

Gut. 2018 Nov;67(11):2045-2053. doi: 10.1136/gutjnl-2017-313811. Epub 2017 Sep 26.

PMID:
28951526
16.

Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience.

Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, Andersson MI.

PLoS One. 2017 Jul 21;12(7):e0181267. doi: 10.1371/journal.pone.0181267. eCollection 2017.

17.

Prüfung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren zur Anwendung im human-medizinischen Bereich : Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut.

Schwebke I, Eggers M, Gebel J, Geisel B, Glebe D, Rapp I, Steinmann J, Rabenau F.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Mar;60(3):353-363. doi: 10.1007/s00103-016-2509-2. German. No abstract available.

PMID:
28220216
19.

Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes.

Hassemer M, Finkernagel M, Peiffer KH, Glebe D, Akhras S, Reuter A, Scheiblauer H, Sommer L, Chudy M, Nübling CM, Hildt E.

Virology. 2017 Feb;502:1-12. doi: 10.1016/j.virol.2016.12.003. Epub 2016 Dec 9.

20.

Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony-stimulating factor treatment.

Punzel M, Medd P, Hunter H, Cunningham R, Pottinger B, Burde B, Widera M, Quade A, Ehninger G, Kozlova A, Schmidt H, Buhrmann K, Schüttler CG, Glebe D, Billen A, Schmidt AH, Mengling T, Verheyen J.

Hepatology. 2016 Nov;64(5):1803-1805. doi: 10.1002/hep.28667. Epub 2016 Jul 9. No abstract available.

PMID:
27240006
21.

Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine.

Gerlich WH, Glebe D.

EBioMedicine. 2016 Sep;11:5-6. doi: 10.1016/j.ebiom.2016.07.032. Epub 2016 Jul 27. No abstract available.

22.

International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen.

Wilkinson DE, Seiz PL, Schüttler CG, Gerlich WH, Glebe D, Scheiblauer H, Nick S, Chudy M, Dougall T, Stone L, Heath AB; Collaborative Study Group.

J Clin Virol. 2016 Sep;82:173-180. doi: 10.1016/j.jcv.2016.06.003. Epub 2016 Jun 6.

23.

Characterization of the 3rd International Standard for hepatitis B virus surface antigen (HBsAg).

Seiz PL, Mohr C, Wilkinson DE, Ziebuhr J, Schüttler CG, Gerlich WH, Glebe D.

J Clin Virol. 2016 Sep;82:166-172. doi: 10.1016/j.jcv.2016.05.009. Epub 2016 Jun 3.

PMID:
27345250
24.

Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.

Montalbano R, Honrath B, Wissniowski TT, Elxnat M, Roth S, Ocker M, Quint K, Churin Y, Roederfeld M, Schroeder D, Glebe D, Roeb E, Di Fazio P.

Oncotarget. 2016 Apr 12;7(15):20312-23. doi: 10.18632/oncotarget.7950.

25.

Identification of valid reference genes for microRNA expression studies in a hepatitis B virus replicating liver cell line.

Jacobsen KS, Nielsen KO, Winther TN, Glebe D, Pociot F, Hogh B.

BMC Res Notes. 2016 Jan 22;9:38. doi: 10.1186/s13104-016-1848-2.

26.

Genomic Methylation Inhibits Expression of Hepatitis B Virus Envelope Protein in Transgenic Mice: A Non-Infectious Mouse Model to Study Silencing of HBV Surface Antigen Genes.

Graumann F, Churin Y, Tschuschner A, Reifenberg K, Glebe D, Roderfeld M, Roeb E.

PLoS One. 2015 Dec 30;10(12):e0146099. doi: 10.1371/journal.pone.0146099. eCollection 2015.

27.

Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection.

Meng Z, Zhang X, Pei R, Zhang E, Kemper T, Vollmer J, Davis HL, Glebe D, Gerlich W, Roggendorf M, Lu M.

Antiviral Res. 2016 Jan;125:14-24. doi: 10.1016/j.antiviral.2015.11.001. Epub 2015 Nov 14.

PMID:
26585244
28.

New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen.

Kucinskaite-Kodze I, Pleckaityte M, Bremer CM, Seiz PL, Zilnyte M, Bulavaite A, Mickiene G, Zvirblis G, Sasnauskas K, Glebe D, Zvirbliene A.

Virus Res. 2016 Jan 4;211:209-21. doi: 10.1016/j.virusres.2015.10.024. Epub 2015 Nov 2.

PMID:
26541316
29.

Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.

Pleckaityte M, Bremer CM, Gedvilaite A, Kucinskaite-Kodze I, Glebe D, Zvirbliene A.

BMC Biotechnol. 2015 Sep 15;15:85. doi: 10.1186/s12896-015-0203-3.

30.

Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression.

Seiz PL, Slanina H, Ziebuhr J, Gerlich WH, Glebe D, Schüttler CG.

Int J Med Microbiol. 2015 Oct;305(7):663-72. doi: 10.1016/j.ijmm.2015.08.016. Epub 2015 Aug 21.

PMID:
26338147
31.

Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act.

Andersson MI, Rajbhandari R, Kew MC, Vento S, Preiser W, Hoepelman AI, Theron G, Cotton M, Cohn J, Glebe D, Lesi O, Thursz M, Peters M, Chung R, Wiysonge C.

Lancet Glob Health. 2015 Jul;3(7):e358-9. doi: 10.1016/S2214-109X(15)00056-X. No abstract available.

32.

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood.

Qawasmi M, Samuh M, Glebe D, Gerlich WH, Azzeh M.

Hum Vaccin Immunother. 2015;11(7):1717-24. doi: 10.1080/21645515.2015.1041687.

33.

Correction: pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, Zahner D, Ocker M, Gerlich W, Glebe D, Roeb E.

PLoS One. 2015 May 1;10(5):e0127375. doi: 10.1371/journal.pone.0127375. eCollection 2015. No abstract available.

34.

A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity.

Cerino A, Bremer CM, Glebe D, Mondelli MU.

PLoS One. 2015 Apr 29;10(4):e0125704. doi: 10.1371/journal.pone.0125704. eCollection 2015.

35.

[Guideline of the German Association for the Control of Viral Diseases (DVV) eV and the Robert Koch Institute (RKI) for testing chemical disinfectants for effectiveness against viruses in human medicine. Version of 1 December, 2014].

Rabenau HF, Schwebke I, Blümel J, Eggers M, Glebe D, Rapp I, Sauerbrei A, Steinmann E, Steinmann J, Willkommen H, Wutzler P.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Apr;58(4-5):493-504. doi: 10.1007/s00103-015-2131-8. German. No abstract available.

PMID:
25893886
36.

[Communication from the German Association for the Control of Viral Diseases. (DVV) and the Robert Koch Institute (RKI) Publication of the updated version of the guideline for testing chemical disinfectants for effectiveness against viruses in human medicine (suspension test) - version December 1, 2014].

Schwebke I, Blümel J, Eggers M, Glebe D, Rapp I, von Rheinbaben F, Sauerbrei A, Steinmann E, Steinmann J, Willkommen H, Wutzler P, Rabenau HF.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Apr;58(4-5):491-2. doi: 10.1007/s00103-015-2130-9. German. No abstract available.

PMID:
25893885
37.

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.

Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, Taranta A, Manns MP, Wedemeyer H, Glebe D, Cornberg M.

Clin Microbiol Infect. 2015 Jun;21(6):606.e1-10. doi: 10.1016/j.cmi.2015.02.010. Epub 2015 Feb 17.

38.

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.

Geipel A, Seiz PL, Niekamp H, Neumann-Fraune M, Zhang K, Kaiser R, Protzer U, Gerlich WH, Glebe D; HOPE Consortium.

Antivir Ther. 2015;20(8):779-87. doi: 10.3851/IMP2928. Epub 2015 Jan 5.

PMID:
25560463
39.

Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine.

Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azzeh M.

PLoS One. 2014 Dec 12;9(12):e113821. doi: 10.1371/journal.pone.0113821. eCollection 2014.

40.

Genotyping and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan.

Yousif M, Mudawi H, Hussein W, Mukhtar M, Nemeri O, Glebe D, Kramvis A.

Int J Infect Dis. 2014 Dec;29:125-32. doi: 10.1016/j.ijid.2014.07.002. Epub 2014 Oct 24.

41.

Overt and occult hepatitis B virus infection in adult Sudanese HIV patients.

Mudawi H, Hussein W, Mukhtar M, Yousif M, Nemeri O, Glebe D, Kramvis A.

Int J Infect Dis. 2014 Dec;29:65-70. doi: 10.1016/j.ijid.2014.07.004. Epub 2014 Oct 24.

42.

Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.

Peiffer KH, Akhras S, Himmelsbach K, Hassemer M, Finkernagel M, Carra G, Nuebling M, Chudy M, Niekamp H, Glebe D, Sarrazin C, Zeuzem S, Hildt E.

J Hepatol. 2015 Apr;62(4):791-8. doi: 10.1016/j.jhep.2014.11.028. Epub 2014 Nov 28.

PMID:
25445396
43.

More on hepatitis B virus rtI233V mutation and resistance to adefovir.

Geipel A, Glebe D, Gerlich WH.

N Engl J Med. 2014 Jul 31;371(5):483. doi: 10.1056/NEJMc1406607. No abstract available.

PMID:
25075851
44.

Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.

Glebe D, Geipel A.

Intervirology. 2014;57(3-4):225-31. doi: 10.1159/000360950. Epub 2014 Jul 15. Review.

45.

Molecular virology of hepatitis B virus and targets for antiviral intervention.

Glebe D, König A.

Intervirology. 2014;57(3-4):134-40. doi: 10.1159/000360946. Epub 2014 Jul 15. Review.

46.

Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.

König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D.

J Hepatol. 2014 Oct;61(4):867-75. doi: 10.1016/j.jhep.2014.05.018. Epub 2014 May 15.

PMID:
24845614
47.

Hepatitis B virus rtI233V mutation and resistance to adefovir.

Geipel A, Glebe D, Will H, Gerlich WH.

N Engl J Med. 2014 Apr 24;370(17):1667-8. doi: 10.1056/NEJMc1400292. No abstract available.

PMID:
24758635
48.

Analysis of ultra-deep pyrosequencing and cloning based sequencing of the basic core promoter/precore/core region of hepatitis B virus using newly developed bioinformatics tools.

Yousif M, Bell TG, Mudawi H, Glebe D, Kramvis A.

PLoS One. 2014 Apr 16;9(4):e95377. doi: 10.1371/journal.pone.0095377. eCollection 2014.

49.

Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, Zahner D, Ocker M, Gerlich W, Glebe D, Roeb E.

PLoS One. 2014 Mar 4;9(3):e90608. doi: 10.1371/journal.pone.0090608. eCollection 2014. Erratum in: PLoS One. 2015;10(5):e0127375.

50.

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Möller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M.

PLoS Pathog. 2014 Jan;10(1):e1003856. doi: 10.1371/journal.ppat.1003856. Epub 2014 Jan 2.

Supplemental Content

Support Center